ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palmqvist, M
Right arrow Articles by Lotvall, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmqvist, M
Right arrow Articles by Lotvall, J
Eur Respir J 1997; 10: 2484-2489
Copyright © ERS Journals Ltd 1997


Clinical Trial

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

M Palmqvist, G Persson, L Lazer, J Rosenborg, P Larsson, and J Lotvall

Salmeterol and formoterol are two long-acting beta2-agonists for inhalation, currently being used in clinical practice. The aim of the present study was to investigate the onset of action, duration of effect and potency of these two beta2-agonists in asthmatic patients. Patients (n=28) were included on the basis of salbutamol stepwise reversibility (100, 100 and 200 microg, given cumulatively; total reversibility > or =15%). In a double-blind placebo-controlled crossover study, the bronchodilating properties of formoterol 6, 12 and 24 microg were compared with the effects of salmeterol 50 microg. Formoterol was given via Turbuhaler and salmeterol via Diskhaler, and forced expiratory volume in one second (FEV1) was monitored during 12 h. Formoterol at all doses had a more rapid onset than salmeterol as judged from bronchodilation at 3 min after the dose. Formoterol at all doses had a similar duration of effect to salmeterol 50 microg, as judged from bronchodilation at 12 h after dose administration. When the relative potency of the two drugs was compared, salmeterol 50 microg was estimated to correspond to formoterol 9 microg (95% confidence interval: 3-19 microg). We confirm that formoterol and salmeterol are both long-acting beta2-agonists, but with some differences in effect profile. We confirm the more rapid onset of action of formoterol compared with salmeterol, and furthermore, no difference in duration of effect is evident.


This article has been cited by other articles:


Home page
Eur Respir JHome page
A. R. Rubinfeld, R. Scicchitano, A. Hunt, P. J. Thompson, A. Van Nooten, and O. Selroos
Formoterol Turbuhaler as reliever medication in patients with acute asthma
Eur. Respir. J., April 1, 2006; 27(4): 735 - 741.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. P. Parsons and J. G. Mastronarde
Exercise-Induced Bronchoconstriction in Athletes
Chest, December 1, 2005; 128(6): 3966 - 3974.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. Vogelmeier, A. D'Urzo, R. Pauwels{dagger}, J. M. Merino, M. Jaspal, S. Boutet, I. Naya, and D. Price
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Eur. Respir. J., November 1, 2005; 26(5): 819 - 828.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. Jenkins
Formoterol as relief medication in asthma: the jury is still out
Eur. Respir. J., November 1, 2003; 22(5): 723 - 724.
[Full Text] [PDF]


Home page
ChestHome page
U. G. Lalloo, J. Malolepszy, D. Kozma, K. Krofta, J. Ankerst, B. Johansen, and N. C. Thomson
Budesonide and Formoterol in a Single Inhaler Improves Asthma Control Compared With Increasing the Dose of Corticosteroid in Adults With Mild-to-Moderate Asthma
Chest, May 1, 2003; 123(5): 1480 - 1487.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P.W. Ind, C. Villasante, R.J. Shiner, A. Pietinalho, N.G. Boszormenyi, S. Soliman, and O. Selroos
Safety of formoterol by Turbuhaler(R) as reliever medication compared with terbutaline in moderate asthma
Eur. Respir. J., October 1, 2002; 20(4): 859 - 866.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
D Price, D Dutchman, A Mawson, B Bodalia, S Duggan, and P Todd
Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose
Thorax, September 1, 2002; 57(9): 791 - 798.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
N. A. Hanania, A. Sharafkhaneh, R. Barber, and B. F. Dickey
{beta}-Agonist Intrinsic Efficacy: Measurement and Clinical Significance
Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1353 - 1358.
[Full Text] [PDF]


Home page
Eur Respir JHome page
K. Richter, S. Janicki, R.A. Jorres, and H. Magnussen
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline
Eur. Respir. J., May 1, 2002; 19(5): 865 - 871.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. A. Nightingale, D. F. Rogers, and P. J. Barnes
Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma*
Chest, May 1, 2002; 121(5): 1401 - 1406.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
R.I. Ketchell, M.W. Jensen, D. Spina, and B.J. O'Connor
Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine
Eur. Respir. J., April 1, 2002; 19(4): 611 - 616.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Malolepszy, G. Boszormenyi Nagy, O. Selroos, P. Larsson, and R. Brander
Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction
Eur. Respir. J., December 1, 2001; 18(6): 928 - 934.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]


Home page
ThoraxHome page
H J van der Woude, T H Winter, and R Aalbers
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting {beta}2 agonists
Thorax, July 1, 2001; 56(7): 529 - 535.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D.C. Grootendorst, P.J. Sterk, and H.G.M. Heijerman
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Eur. Respir. J., March 1, 2001; 17(3): 374 - 379.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. PALMQVIST, T. IBSEN, A. MELLÉN, and J. LÖTVALL
Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients
Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.